New antibody combo takes on Hard-to-Treat cancers

NCT ID NCT05856981

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests an experimental drug called ADU-1805, alone or combined with the immunotherapy Keytruda, in adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety and find the right dose. About 130 participants will take part across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ADU-1805 (an experimental antibody) and pembrolizumab (Keytruda)
What this could lead to
If successful, this could lead to a new treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial with a small number of participants, so safety and effectiveness are not yet known. The drug may cause side effects or fail to shrink tumors.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CRC (COLORECTAL CANCER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Gabrail Cancer & Research Center

    RECRUITING

    Canton, Ohio, 44718, United States

    Contact

  • Grand Hopital de Charleroi (GHdC) - Hopital Notre Dame

    RECRUITING

    Charleroi, Belgium

    Contact

  • Henry Ford Cancer Institute

    RECRUITING

    Detroit, Michigan, 48202, United States

    Contact

  • Hosp 12 de Octubre

    RECRUITING

    Madrid, Spain

    Contact

  • Hospital General Universitario Gergorio Maranon

    RECRUITING

    Madrid, Spain

    Contact

  • Virginia Cancer Specialists

    RECRUITING

    Fairfax, Virginia, 22205, United States

    Contact

  • Washington University Medical Campus

    RECRUITING

    St Louis, Missouri, 63110, United States

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.